NASDAQ · MLTX
MoonLake Immunotherapeutics
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MLTX: Nov 4, 2026
MoonLake Immunotherapeutics Class A Ordinary Shares is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.77. The reported EPS for the same quarter last year was $-1.1.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.77 | $-0.70 | $-0.88 | 4 |
| Dec 2026 | $-0.81 | $-0.69 | $-0.93 | 4 |
| Mar 2027 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Jun 2027 | $-0.72 | $-0.72 | $-0.72 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool- RTTNews · Aug 10, 10:10 AM EDTMoonLake's Sonelokimab Meets All Endpoints In Phase 3 PsA Trial(RTTNews) – MoonLake Immunotherapeutics (MLTX) announced positive topline results from its Phase 3 IZAR-1 trial evaluating Sonelokimab in biologic-naïve adults with active psoriatic arthritis.
- Zacks · Jul 31, 9:55 AM EDTWall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- The Motley Fool · Jul 3, 10:34 AM EDTMoonLake Immunotherapeutics' CFO Sells 39K SharesThe executive sold 39,120 shares on June 22.
- The Motley Fool · Jun 24, 8:09 PM EDTWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayIt aims to raise up to $200 million in the offering.
- RTTNews · Jun 24, 12:56 AM EDTMoonLake Prices Upsized $200 Million Offering To Advance Sonelokimab Program(RTTNews) – MoonLake Immunotherapeutics (MLTX) has priced an upsized $200 million public offering as the company moves to accelerate development and potential commercialization activities for its lead inflammatory disease candidate, Sonelokimab.
- RTTNews · Jun 23, 1:51 AM EDTMoonLake Immunotherapeutics Unveils $150 Mln Of Shares And Warrants; Stock Down(RTTNews) – MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases, announced a $150 million public offering of class A ordinary shares and pre-funded warrants to purchase class A ordinar
- RTTNews · Jun 22, 1:55 AM EDTMoonLake Soars On Positive 52-week Data Of Sonelokimab In Hidradenitis Suppurativa(RTTNews) – MoonLake Immunotherapeutics (MLTX), a clinical-stage biotechnology company, on Monday announced positive 52 week results from the Phase 3 registrational VELA-1 and VELA-2 clinical trials evaluating Sonelokimab in patients with moderate-to-severe hidradenitis suppurat
- The Motley Fool · Jun 4, 10:19 PM EDTMoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?Bodenstedt sold 13,653 shares for a transaction value of ~$273,000 at around $20.02 per share on May 11, 2026.
- RTTNews · May 11, 6:32 AM EDTMoonLake Completes Pre-BLA Meeting With FDA; Records Q1 Loss Of $69 Mln(RTTNews) – MoonLake Immunotherapeutics Inc. (MLTX), a clinical-stage biopharmaceutical company, on Sunday, announced that its pre-BLA meeting with the FDA regarding its Hidradenitis suppurativa drug candidate sonelokimab yielded positive feedback, and it also reported financial
- The Motley Fool · Apr 18, 10:37 AM EDTThe CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share.
- The Motley Fool · Apr 7, 2:27 PM EDTBiotech Fund BVF Trims MoonLake Stake, Sells $63M in SharesBVF sold 3,750,000 shares for a transaction value of approximately $62.96 million on April 2, 2026.
- RTTNews · Mar 30, 4:27 AM EDTMoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75(RTTNews) – MoonLake Immunotherapeutics (MLTX) announced on March 28, 2026, the Week 40 results from its Phase 3 VELA programs in hidradenitis suppurativa, showing that clinical responses continued to improve well beyond the initial 16-week primary endpoint.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for MoonLake Immunotherapeutics from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.